Suppr超能文献

盘尾丝虫病的化疗X. MK-933(伊维菌素)四种单剂量治疗方案治疗人类盘尾丝虫病的评估

The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis.

作者信息

Awadzi K, Dadzie K Y, Shulz-Key H, Haddock D R, Gilles H M, Aziz M A

出版信息

Ann Trop Med Parasitol. 1985 Feb;79(1):63-78.

PMID:3838638
Abstract

Nineteen patients from an area of vector control in the savanna region of Northern Ghana, all with moderate to heavy infections with Onchocerca volvulus and some with ocular involvement, were treated with 50, 100, 150 or 200 micrograms kg-1 of ivermectin. Detailed monitoring of clinical and ocular reactions and of alterations in skin microfilarial counts and laboratory indices were carried out during the first 28 days. Microfilarial counts in skin snips and detailed ocular examinations were then repeated at intervals over a period of nine months. Ivermectin slowly eliminated microfilariae from the skin and eye without serious adverse clinical or ocular reactions in all treated groups. There was little difference in efficacy between doses of 100, 150 and 200 micrograms kg-1, and these were more effective than the 50 micrograms kg-1 dose. Very low levels of skin microfilariae were maintained for nine months. Microfilariae were not eliminated from the eye for at least three months. The drug was neither macrofilaricidal nor embryotoxic. However, it produced a dose-dependent stimulation of embryogenesis manifest at one month and succeeded by a suppression of embryogenesis at three months after therapy. In areas where transmission of onchocerciasis has been interrupted, ivermectin may need not be given more often than once a year. The efficacy of the drug on single dosage and the mild adverse reactions produced, if confirmed in subsequent controlled studies, would greatly simplify the treatment of onchocerciasis and would reintroduce new concepts of the role of chemotherapy in the control of onchocerciasis.

摘要

来自加纳北部稀树草原地区一个病媒控制区的19名患者,均感染了中度至重度的盘尾丝虫,部分患者有眼部受累,接受了50、100、150或200微克/千克体重的伊维菌素治疗。在最初的28天内,对临床和眼部反应以及皮肤微丝蚴计数和实验室指标的变化进行了详细监测。然后在九个月的时间里定期重复进行皮肤切片微丝蚴计数和详细的眼部检查。伊维菌素在所有治疗组中都能缓慢地从皮肤和眼睛中清除微丝蚴,且无严重的临床或眼部不良反应。100、150和200微克/千克体重剂量之间的疗效差异不大,且这些剂量比50微克/千克体重剂量更有效。皮肤微丝蚴水平在九个月内维持在非常低的水平。微丝蚴至少三个月未从眼睛中清除。该药物既不杀成虫也不具有胚胎毒性。然而,它在治疗后一个月产生了剂量依赖性的胚胎发生刺激作用,随后在三个月时出现胚胎发生抑制作用。在盘尾丝虫病传播已被阻断的地区,伊维菌素可能每年给药一次就足够了。如果在后续的对照研究中得到证实,该药物单次给药的疗效以及产生的轻微不良反应将大大简化盘尾丝虫病的治疗,并将重新引入化疗在盘尾丝虫病控制中作用的新观念。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验